AMGEN FIRST YEAR EPOGEN SALES BOOST FY 1990 REVENUES 155% TO $199 MIL.
Amgen Epogen sales are annualizing at over $200 mil. based on sales of the product in the three months ended March 31. The Thousand Oaks, Calif. biotech firm said its product sales, derived almost entirely from Epogen, were $53.6 mil. in the company's fourth fiscal quarter ended March 31, up from $806,000 for the same period last year. For fiscal 1990, Amgen reported product sales of $152.2 mil., up from $2.7 mil. in fiscal 1989. Although Amgen did not specifically break out Epogen sales, the company's product sales figures indicate that the erythropoietin product generated approximately $150 mil. in sales in the 10 months since its launch. Amgen revenues more than doubled in fiscal 1990 to $199 mil. Fiscal 1989 revenues of $78.1 mil. stemmed primarily from corporate partner revenues of $67.4 mil. and interest income of$7.9 mil. Epogen currently is received by an estimated 55,000 patients with anemia associated with chronic renal failure, representing "over 60% of those dialysis patients eligible for Epogen therapy," Amgen CEO Gordon Binder commented. The company reported a profit for the year of $19.1 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth